|
US511A
(en)
*
|
|
1837-12-15 |
|
Improved mode of coloring and finishing leather |
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4440859A
(en)
|
1977-05-27 |
1984-04-03 |
The Regents Of The University Of California |
Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
|
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
|
DD147855A5
(de)
|
1978-12-22 |
1981-04-22 |
Biogen Nv |
Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4530901A
(en)
|
1980-01-08 |
1985-07-23 |
Biogen N.V. |
Recombinant DNA molecules and their use in producing human interferon-like polypeptides
|
|
CA1200773A
(en)
|
1980-02-29 |
1986-02-18 |
William J. Rutter |
Expression linkers
|
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
|
US4678751A
(en)
|
1981-09-25 |
1987-07-07 |
Genentech, Inc. |
Hybrid human leukocyte interferons
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4766075A
(en)
|
1982-07-14 |
1988-08-23 |
Genentech, Inc. |
Human tissue plasminogen activator
|
|
US4582800A
(en)
|
1982-07-12 |
1986-04-15 |
Hoffmann-La Roche Inc. |
Novel vectors and method for controlling interferon expression
|
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
JPS60188070A
(ja)
|
1984-03-09 |
1985-09-25 |
Kunio Yamane |
シグナルペプチドをコードするｄｎａ
|
|
GB8412517D0
(en)
|
1984-05-16 |
1984-06-20 |
Nagai K |
Recombinant fusion proteins
|
|
CA1282721C
(en)
|
1984-06-04 |
1991-04-09 |
Bernard Roizman |
Herpes simplex virus as a vector
|
|
US4677063A
(en)
|
1985-05-02 |
1987-06-30 |
Cetus Corporation |
Human tumor necrosis factor
|
|
CA1341423C
(en)
|
1984-10-31 |
2003-03-04 |
Paul A. Luciw |
Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
|
|
US5036006A
(en)
|
1984-11-13 |
1991-07-30 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
EP0228458B2
(en)
|
1985-07-05 |
1997-10-22 |
Whitehead Institute For Biomedical Research |
Epithelial cells expressing foreign genetic material
|
|
KR890003620Y1
(ko)
|
1985-07-25 |
1989-05-27 |
삼성전자주식회사 |
전자레인지의 파워릴레이 구동회로
|
|
CA1293460C
(en)
|
1985-10-07 |
1991-12-24 |
Brian Lee Sauer |
Site-specific recombination of dna in yeast
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US4810648A
(en)
|
1986-01-08 |
1989-03-07 |
Rhone Poulenc Agrochimie |
Haloarylnitrile degrading gene, its use, and cells containing the gene
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5084384A
(en)
|
1987-04-23 |
1992-01-28 |
Monsanto Company |
Secretion of insulin-like growth factor-I
|
|
US6093699A
(en)
|
1987-07-09 |
2000-07-25 |
The University Of Manitoba |
Method for gene therapy involving suppression of an immune response
|
|
US5017478A
(en)
|
1987-07-16 |
1991-05-21 |
Berlex Laboratories, Inc. |
Transfected cells containing plasmids having genes oriented in opposing directions and methods of using
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
ZA887365B
(en)
|
1987-10-02 |
1990-05-30 |
Genentech Inc |
Adheson variants
|
|
US6710169B2
(en)
*
|
1987-10-02 |
2004-03-23 |
Genentech, Inc. |
Adheson variants
|
|
US5336603A
(en)
*
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
NZ226414A
(en)
|
1987-10-02 |
1992-07-28 |
Genentech Inc |
Cd4 peptide adhesion variants and their preparation and use
|
|
ES2092468T3
(es)
|
1988-01-22 |
1996-12-01 |
Zymogenetics Inc |
Metodos para producir analogos de receptores secretados.
|
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
|
US6018026A
(en)
*
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5614404A
(en)
|
1988-06-10 |
1997-03-25 |
Theriod Biologics, Incorporated |
Self-assembled, defective, non-self-propagating lentivirus particles
|
|
US5284768A
(en)
|
1988-08-24 |
1994-02-08 |
Sanofi |
Signal peptide, DNA sequences coding for the latter, expression vectors carrying one of these sequences, gram-negative bacteria transformed by these vectors, and process for the periplasmic production of a polypeptide
|
|
US5349052A
(en)
|
1988-10-20 |
1994-09-20 |
Royal Free Hospital School Of Medicine |
Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
|
|
US6685941B1
(en)
*
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
DE3901681A1
(de)
|
1989-01-21 |
1990-07-26 |
Behringwerke Ag |
Signalpeptid fuer die sekretion von peptiden in escherichia coli, verfahren zu seiner gewinnung und seine verwendung
|
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US6406697B1
(en)
*
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5082767A
(en)
|
1989-02-27 |
1992-01-21 |
Hatfield G Wesley |
Codon pair utilization
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
|
US5672683A
(en)
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
ATE212672T1
(de)
|
1989-10-24 |
2002-02-15 |
Chiron Corp |
System zur freisetzung von infektiösen proteinen
|
|
AU625013B2
(en)
|
1989-11-03 |
1992-06-25 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
US5697901A
(en)
|
1989-12-14 |
1997-12-16 |
Elof Eriksson |
Gene delivery by microneedle injection
|
|
US5672510A
(en)
|
1990-01-19 |
1997-09-30 |
Genetic Therapy, Inc. |
Retroviral vectors
|
|
US7070776B1
(en)
*
|
1990-03-26 |
2006-07-04 |
Bristol-Myers Squibb Company |
Methods for blocking binding of CD28 receptor to B7
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
SE9003978D0
(sv)
|
1990-12-13 |
1990-12-13 |
Henrik Garoff |
Dna expressionssystem baserade paa ett virus replikon
|
|
EP0576612B1
(en)
|
1991-03-19 |
1999-12-01 |
Cytrx Corporation |
Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
|
|
JP3722375B2
(ja)
*
|
1991-06-27 |
2005-11-30 |
ブリストル−マイヤーズ スクイブ カンパニー |
Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
|
|
US6090914A
(en)
|
1991-06-27 |
2000-07-18 |
Bristol-Myers Squibb Company |
CTLA4/CD28Ig hybrid fusion proteins and uses thereof
|
|
US5770197A
(en)
*
|
1991-06-27 |
1998-06-23 |
Bristol-Myers Squibb Company |
Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
|
|
US5851795A
(en)
*
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5844095A
(en)
*
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
US5637481A
(en)
*
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5506098A
(en)
|
1991-09-04 |
1996-04-09 |
Daikin Industries, Ltd. |
In situ hybridization method
|
|
US5635532A
(en)
|
1991-10-21 |
1997-06-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
|
|
ATE272708T1
(de)
|
1992-04-07 |
2004-08-15 |
Univ Michigan |
Immunregulation über die cd28-route
|
|
US5792751A
(en)
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
|
IL105914A0
(en)
|
1992-06-04 |
1993-10-20 |
Univ California |
Methods and compositions for in vivo gene therapy
|
|
EP0671926B1
(en)
|
1992-08-11 |
2002-11-13 |
President And Fellows Of Harvard College |
Immunomodulatory peptides
|
|
WO1994012520A1
(en)
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
|
DE69329974T2
(de)
|
1992-12-04 |
2001-07-19 |
Medical Research Council, London |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
US5633234A
(en)
|
1993-01-22 |
1997-05-27 |
The Johns Hopkins University |
Lysosomal targeting of immunogens
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
EP0621337A1
(en)
|
1993-01-25 |
1994-10-26 |
American Cyanamid Company |
Codon optimized DNA sequence for insect toxin AaIT
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
US5981505A
(en)
|
1993-01-26 |
1999-11-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for delivery of genetic material
|
|
US6482919B2
(en)
*
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
DE69435075T2
(de)
|
1993-03-17 |
2009-02-19 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
|
|
TW404844B
(en)
|
1993-04-08 |
2000-09-11 |
Oxford Biosciences Ltd |
Needleless syringe
|
|
CA2161122A1
(fr)
|
1993-04-21 |
1994-10-27 |
Philippe Moullier |
Implant biocompatible pour l'expression et secretion in vivo d'un compose therapeutique
|
|
US5591601A
(en)
|
1993-05-14 |
1997-01-07 |
Ohio University Edison Animal Biotechnology Institute |
DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
|
|
US6133028A
(en)
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
|
US5804566A
(en)
|
1993-08-26 |
1998-09-08 |
The Regents Of The University Of California |
Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
|
|
US5679647A
(en)
|
1993-08-26 |
1997-10-21 |
The Regents Of The University Of California |
Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
|
|
US5849719A
(en)
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
|
US5830877A
(en)
|
1993-08-26 |
1998-11-03 |
The Regents Of The University Of California |
Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
|
|
US5426039A
(en)
|
1993-09-08 |
1995-06-20 |
Bio-Rad Laboratories, Inc. |
Direct molecular cloning of primer extended DNA containing an alkane diol
|
|
ATE257176T1
(de)
|
1993-09-15 |
2004-01-15 |
Chiron Corp |
Rekombinanter alphavirus vektor
|
|
US6107095A
(en)
|
1993-11-26 |
2000-08-22 |
Mazurkiewicz; Marian |
Method for introducing substances into living cells and tissues
|
|
US5580766A
(en)
|
1994-01-14 |
1996-12-03 |
Alexion Pharmaceuticals, Inc. |
Retroviral vector particles for transducing non-proliferating cells
|
|
ES2247248T3
(es)
|
1994-01-21 |
2006-03-01 |
Powderject Vaccines, Inc. |
Instrumento de administracion de genes movido por gas comprimido.
|
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
|
US6077835A
(en)
|
1994-03-23 |
2000-06-20 |
Case Western Reserve University |
Delivery of compacted nucleic acid to cells
|
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
|
GB9406974D0
(en)
|
1994-04-08 |
1994-06-01 |
Pharmaceutical Proteins Ltd |
Transgenic production
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
JP3816518B2
(ja)
|
1994-06-10 |
2006-08-30 |
ジェンベク、インコーポレイティッド |
相補的なアデノウイルスベクター系と細胞系
|
|
US5601820A
(en)
|
1994-07-07 |
1997-02-11 |
Children's Hospital Of Philadelphia |
Compositions and methods of making and using human full length TRK-B
|
|
US5855579A
(en)
*
|
1994-07-15 |
1999-01-05 |
Smith & Nephew, Inc. |
Cannulated modular intramedullary nail
|
|
EP1181937A3
(en)
|
1994-08-09 |
2004-02-04 |
Cytrx Corporation |
Novel vaccine adjuvant and vaccine
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
GB9502879D0
(en)
|
1995-02-14 |
1995-04-05 |
Oxford Biosciences Ltd |
Particle delivery
|
|
US6127525A
(en)
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
|
US5750340A
(en)
|
1995-04-07 |
1998-05-12 |
University Of New Mexico |
In situ hybridization solution and process
|
|
US5922687A
(en)
|
1995-05-04 |
1999-07-13 |
Board Of Trustees Of The Leland Stanford Junior University |
Intracellular delivery of nucleic acids using pressure
|
|
US5525510A
(en)
|
1995-06-02 |
1996-06-11 |
Agracetus, Inc. |
Coanda effect gene delivery instrument
|
|
DE69634297T2
(de)
|
1995-06-05 |
2006-01-05 |
University Of Washington, Seattle |
Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
|
|
US5993800A
(en)
*
|
1995-06-05 |
1999-11-30 |
Bristol-Myers Squibb Company |
Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
|
|
US5668110A
(en)
|
1995-06-07 |
1997-09-16 |
Affymax Technologies N.V. |
Peptides and compounds that bind to the IL-5 receptor
|
|
US5811406A
(en)
|
1995-06-07 |
1998-09-22 |
Regents Of The University Of California |
Dry powder formulations of polynucleotide complexes
|
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
|
WO1997004748A2
(en)
|
1995-08-01 |
1997-02-13 |
Advanced Therapies, Inc. |
Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
|
|
US5966560A
(en)
*
|
1995-08-29 |
1999-10-12 |
Minolta Co., Ltd. |
Image forming apparatus with enhanced pretransfer erasing
|
|
US5801030A
(en)
|
1995-09-01 |
1998-09-01 |
Genvec, Inc. |
Methods and vectors for site-specific recombination
|
|
US7041634B2
(en)
*
|
1995-09-27 |
2006-05-09 |
Emory University |
Method of inhibiting immune system destruction of transplanted viable cells
|
|
JP2000500121A
(ja)
|
1995-09-27 |
2000-01-11 |
エモリー・ユニバーシティー |
免疫系による生きた被移植細胞の破壊を阻止する方法
|
|
KR970029803A
(ko)
|
1995-11-03 |
1997-06-26 |
김광호 |
반도체 메모리장치의 프리차지 회로
|
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
|
US5789244A
(en)
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
|
US6750334B1
(en)
*
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
ES2243979T3
(es)
*
|
1996-03-04 |
2005-12-01 |
Scios Inc. |
Analisis y reactivos que permite cuantificar el hbnp.
|
|
JP4751493B2
(ja)
|
1996-03-20 |
2011-08-17 |
ブリストル−マイヤーズ スクイッブ カンパニー |
Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
|
|
US6261552B1
(en)
|
1997-05-22 |
2001-07-17 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus vectors
|
|
WO1997044446A1
(en)
|
1996-05-24 |
1997-11-27 |
University Of Maryland At Baltimore |
Dna vaccines for eliciting a mucosal immune response
|
|
US5750356A
(en)
|
1996-05-31 |
1998-05-12 |
Anergen, Inc. |
Method for monitoring T cell reactivity
|
|
GB9619002D0
(en)
|
1996-09-11 |
1996-10-23 |
Oxford Biosciences Ltd |
Particle delivery
|
|
EP0987326A4
(en)
|
1996-07-11 |
2002-11-06 |
Takara Shuzo Co |
METHOD FOR PERFORMING A DIRECTED MUTAGENESIS
|
|
DE69725857T2
(de)
|
1996-08-14 |
2004-07-29 |
The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer |
Vektor für polynukleotidimpfstoffe
|
|
US6211160B1
(en)
|
1996-09-06 |
2001-04-03 |
The Trustees Of The University Of Pennsylvania |
Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
US6107477A
(en)
|
1996-09-26 |
2000-08-22 |
Aurora Biosciences Corporation |
Non-optimal Kozaks sequences
|
|
CN1183968C
(zh)
|
1996-10-23 |
2005-01-12 |
宾夕法尼亚州立大学托管会 |
改良疫苗
|
|
WO1998022588A2
(en)
|
1996-11-20 |
1998-05-28 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
|
AU745409B2
(en)
|
1997-01-29 |
2002-03-21 |
Cornell Research Foundation Inc. |
Multiple site delivery of adenoviral vector for the induction of angiogenesis
|
|
ZA98533B
(en)
*
|
1997-01-31 |
1999-07-22 |
Bristol Myers Squibb Co |
Soluble CTLA4 mutant molecules and uses thereof.
|
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
|
DK1023107T3
(da)
|
1997-04-03 |
2006-12-27 |
Electrofect As |
Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
|
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
|
US6225082B1
(en)
|
1997-05-09 |
2001-05-01 |
Research Corporation Technologies, Inc. |
Myelin basic protein MRNA transport and translation enhancer sequences
|
|
DE69819150T3
(de)
|
1997-06-06 |
2007-12-20 |
Dynavax Technologies Corp., San Diego |
Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
|
|
DE69820450T2
(de)
|
1997-06-09 |
2004-05-27 |
Genvec, Inc. |
Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
|
|
DE19729058A1
(de)
|
1997-07-08 |
1999-01-14 |
Sika Ag |
Verbundelement und Verfahren zu seiner Herstellung
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US20010007860A1
(en)
|
1997-07-14 |
2001-07-12 |
Christopher W. Olsen |
Method of dna vaccination
|
|
WO1999008689A1
(en)
|
1997-08-21 |
1999-02-25 |
Powderject Vaccines, Inc. |
Mucosal immunization using particle-mediated delivery techniques
|
|
AU749856B2
(en)
|
1997-09-23 |
2002-07-04 |
Genvec, Inc. |
Plasmids for construction of eukaryotic viral vectors
|
|
US5932445A
(en)
|
1997-11-07 |
1999-08-03 |
Incyte Pharmaceuticals, Inc. |
Signal peptide-containing proteins
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
EP1053312A2
(en)
|
1998-02-11 |
2000-11-22 |
Maxygen, Inc. |
Optimization of immunomodulatory properties of genetic vaccines
|
|
US6087341A
(en)
|
1998-02-12 |
2000-07-11 |
The Board Of Trustees Of The Leland Standford Junior University |
Introduction of nucleic acid into skin cells by topical application
|
|
US5922576A
(en)
|
1998-02-27 |
1999-07-13 |
The John Hopkins University |
Simplified system for generating recombinant adenoviruses
|
|
US6852847B1
(en)
|
1998-03-19 |
2005-02-08 |
Heska Corporation |
Canine and feline B7-2 nucleic acid molecules and uses thereof
|
|
US6121236A
(en)
|
1998-03-24 |
2000-09-19 |
The Children's Medical Center Corporation |
Multivalent ligands which modulate angiogenesis
|
|
BR9909789A
(pt)
|
1998-04-22 |
2000-12-26 |
Genvec Inc |
Método de purificação eficiente de adenovìrus
|
|
CN1297481A
(zh)
|
1998-05-06 |
2001-05-30 |
法玛西雅厄普约翰美国公司 |
向非人脊椎动物导入编码非人脊椎动物肽激素或细胞因子的裸dna或rna
|
|
US6436897B2
(en)
|
1998-06-01 |
2002-08-20 |
Celtrix Pharmaceuticals, Inc. |
Pharmaceutical formulations for IGF/IGFBP
|
|
US5965358A
(en)
|
1998-08-26 |
1999-10-12 |
Genvec, Inc. |
Method for assessing the relative purity of viral gene transfer vector stocks
|
|
AU767975B2
(en)
|
1998-09-11 |
2003-11-27 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
|
US6521419B1
(en)
|
1998-09-22 |
2003-02-18 |
Kanakaraju Koduri |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
|
US6800457B2
(en)
*
|
1998-09-22 |
2004-10-05 |
Bristol-Myers Squibb Company |
Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
|
|
US6225113B1
(en)
|
1998-12-04 |
2001-05-01 |
Genvec, Inc. |
Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
|
|
US6225289B1
(en)
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
|
HK1041274B
(zh)
|
1998-12-23 |
2017-12-01 |
辉瑞大药厂 |
抗ctla-4的人单克隆抗体
|
|
EP1141361B1
(en)
|
1998-12-31 |
2010-04-21 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for packaging of alphavirus vectors
|
|
DK1150918T3
(da)
|
1999-02-03 |
2004-12-20 |
Biosante Pharmaceuticals Inc |
Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
|
|
US6281005B1
(en)
|
1999-05-14 |
2001-08-28 |
Copernicus Therapeutics, Inc. |
Automated nucleic acid compaction device
|
|
AU2001249380A1
(en)
|
2000-03-22 |
2001-11-07 |
Chiron Corporation |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
|
US6168941B1
(en)
|
2000-04-07 |
2001-01-02 |
Genvec, Inc. |
Method of producing adenoviral vector stocks
|
|
US20030170871A1
(en)
|
2000-04-25 |
2003-09-11 |
Chiron Corporation |
Alphavirus-based vectors for persistent infection
|
|
US20020058039A1
(en)
|
2000-04-27 |
2002-05-16 |
Coyne Michael J. |
Method of measuring the duration of adequate immune memory in companion animals
|
|
DK1248802T3
(da)
*
|
2000-05-26 |
2004-11-15 |
Bristol Myers Squibb Co |
Oplöselige CTLA4-mutantmolekyler og anvendelser deraf
|
|
US7094874B2
(en)
*
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
US20050154189A1
(en)
*
|
2000-06-23 |
2005-07-14 |
Maxygen Inc |
Novel co-stimulatory molecules
|
|
CA2411828A1
(en)
*
|
2000-06-23 |
2002-01-03 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
US7183376B2
(en)
*
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
US7074590B2
(en)
|
2000-06-23 |
2006-07-11 |
Maxygen, Inc. |
Chimeric promoters
|
|
US20040022787A1
(en)
*
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
JP2004517806A
(ja)
*
|
2000-07-03 |
2004-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
|
|
AU2001271839A1
(en)
*
|
2000-07-05 |
2002-01-14 |
Pharmacia And Upjohn Company |
Human ion channels
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
AU2002305716B2
(en)
*
|
2001-05-23 |
2007-10-25 |
Bristol-Myers Squibb Company |
Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
|
|
FR2843396B1
(fr)
*
|
2002-08-07 |
2005-04-15 |
Bio Rad Pasteur |
Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
|
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
|
CA2508925C
(en)
*
|
2002-12-23 |
2012-08-28 |
Bristol-Myers Squibb Company |
Product quality enhancement in mammalian cell culture processes for protein production
|
|
BRPI0413326A
(pt)
*
|
2003-08-04 |
2006-10-10 |
Bristol Myers Squibb Co |
métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
|
|
US7731965B2
(en)
*
|
2005-02-17 |
2010-06-08 |
Abbott Lab |
Human ring specific BNP antibodies
|
|
SI1861116T1
(sl)
|
2005-03-25 |
2015-12-31 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonistov VEGF
|
|
PL1868635T3
(pl)
|
2005-04-06 |
2017-10-31 |
Bristol Myers Squibb Co |
Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
WO2009058564A2
(en)
*
|
2007-11-01 |
2009-05-07 |
Maxygen, Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
US9405700B2
(en)
|
2010-11-04 |
2016-08-02 |
Sonics, Inc. |
Methods and apparatus for virtualization in an integrated circuit
|